Related Experiment Video
Updated: Mar 29, 2026

Mouse Model of Metabolic Dysfunction-Associated Steatotic Liver Disease with Fibrosis
Published on: July 18, 2025
Causal Effects of a Hepatic Senescence Gene Set on MASLD Fibrosis: A Mendelian Randomization Study and Quercetin
Zhengwen Li1, Yongzuo Li1, Tianqing Jiang1
1School of Pharmacy, Chengdu University, 2025 Chengluo Avenue, Chengdu 610106, China.
Abstract:
Background: The senescence-associated hepatic gene set (SHGS) is critical in metabolic-dysfunction-associated steatotic liver disease (MASLD) progression. However, causal links between SHGS genes and liver diseases remain unclear. Methods: Mendelian randomization (MR) was used to explore causal relationships between SHGS genes and liver diseases. Immune infiltration of key genes was analyzed using the CIBERSORT algorithm with GEO database data, validated by single-cell RNA sequencing (scRNA-seq). Virtual docking assessed quercetin's potential to modulate SHGS proteins and mitigate liver aging. Results: MR analysis identified elevated GBP2 expression as a risk factor for liver fibrosis (OR = 1.904, p = 0.028) but protective against cholangiocarcinoma (OR = 0.548, p = 0.001). Immune profiling and scRNA-seq revealed GBP2's negative correlation with macrophages in fibrosis and positive correlations with T and NK cells in cholangiocarcinoma. Molecular docking suggested that quercetin indirectly suppresses GBP2 via IRF1, potentially attenuating liver aging. Conclusions: GBP2 might modulate hepatic fibrosis and cholangiocarcinoma. Quercetin may exert antifibrotic effects by indirectly modulating GBP2.
More Related Videos
08:04Isolation of Primary Mouse Hepatocytes for Nascent Protein Synthesis Analysis by Non-radioactive L-azidohomoalanine Labeling Method
Published on: October 23, 2018
09:32Drug-Induced Senescence in Liver Cells Promotes M2 Macrophage Polarization: Implications for Tyrosine Kinase Inhibitor-Associated Hepatotoxicity
Published on: October 17, 2025
Related Concept Videos
Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow
Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test